mRNA-1645

mRNA-1645 is an investigational prophylactic vaccine developed using messenger RNA (mRNA) technology, designed to prevent HIV infection. The vaccine encodes HIV immunogens, specifically including the N332-GT5 gp151 antigen, and is delivered as an mRNA-based formulation. Its mechanism of action involves stimulating the immune system to recognize and mount a response against HIV antigens, thereby providing immunological protection against infection. The drug is being developed by Moderna in collaboration with the HIV Vaccine Trials Network and has reached Phase 1 clinical trials for use in healthy adults at risk of HIV infection[1][2][3].